cb 839 (MedChemExpress)
Structured Review
Cb 839, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 137 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/telaglenastat+cb+839/Telaglenastat/10__1016_slash_j__jpha__2026__101791-113-21-24
Average 96 stars, based on 137 article reviews
Images
Related Articles
other:Article Title: Microglial LNK regulates metabolic reprogramming via competitively inhibiting OTUB1 binding to PKM2 and mitigates ischemic stroke Article Snippet: Compound 3K (PKM2 inhibitor), OTUB1 TFA (OTUB1 inhibitor), Oxamate acid sodium, cycloheximide (CHX), oligomycin, 2- deoxy-D-glucose (2-DG), MG-132 and Article Title: A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer Article Snippet: Article Title: A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer. Article Snippet: Article Title: Real-time NMR analysis of glutamine metabolism for screening anti-cancer agents in living cells Article Snippet: Control:Article Title: Inhibition of glutamine metabolism blocks tumor growth and sensitizes ccRCC to immune checkpoint blockade Article Snippet: .. The following drugs were used in this study: 6-diazo-5-oxo-L-norleucine (DON) (Cat#HY-108357), Sirpiglenastat (DRP-104) (Cat#HY-132832), Article Title: Inhibition of glutamine metabolism blocks tumor growth and sensitizes ccRCC to immune checkpoint blockade. Article Snippet: .. Drugs The following drugs were used in this study: 6-diazo-5-oxo-L- norleucine (DON) (Cat#HY-108357), Sirpiglenastat (DRP-104) (Cat#HY-132832), |
![a , Schematic of [1,2- 13 C]- d -glucose tracing in glycolysis (blue circles) or the pentose phosphate pathway (PPP) (grey circles). b , c , Fractions of labelled pyruvate ( b ) and lactate ( c ) from [1,2- 13 C]- d -glucose in KP -Y and KP -O ( n = 6). d , Schematic of [U 13 C]- l -glutamine tracing (pink circles). e , Mass isotopomer analysis of glutamate (Glu), fumarate (Fum), citrate (Cit) and aspartate (Asp) from [U 13 C]- l -glutamine tracing in KP -Y ( n = 6) and KP -O ( n = 4). f , g , Oxygen consumption rate (OCR) ( f ) and extracellular acidification rate (ECAR) ( g ) in KP -Y ( n = 10) and KP -O ( n = 11). h , i , Mass isotopomer analysis of indicated TCA intermediates from [U 13 C]- l -glutamine tracing in KP -Y, KP -O, KP -Y sh Atf4 .2, KP -O sh Atf4 .2 ( h ) and in KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e ( i ) ( n = 4 per condition). j , Relative viability of KP -Y and KP -O treated <t>with</t> <t>CB-839</t> ( n = 3) k , Heatmap of relative viability for KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle (Veh)-treated controls ( n = 3). l , Anoikis resistance of KP -Y; KP -Y ATF4 o/e; KP -O and KP -O ATF4 o/e treated with 0.1 μM CB-839 for 48 h ( n = 3). m , Heatmap of anoikis resistance of KP -Y and KP -O treated with 0.1 μM CB-839 and the indicated compounds. All data points are relative to vehicle-treated controls ( n = 3). n , o , Lung metastasis burden measured by means of bioluminescence ( n ) or H&E quantification ( o ) (with representative images) in mice after intravenous injections of KP -Y and KP -O and treated with CB-839 or vehicle ( n = 4, 3, 4, 5). p , q , Longitudinal tumour growth of subcutaneous tumours ( KP -Y n = 24, KP -Y + CB-839 n = 22, KP -O n = 26 and KP -O + CB-839 n = 18 tumours) ( p ) and H&E quantification of lung metastases foci ( n = 12, 11, 13 and 9 mice, respectively) ( q ). Mice were administered CB-839 once the tumours reached 100 mm 3 in size. Data are mean ± s.e.m. Two-sided multiple unpaired t -tests ( b , c , e – i , q ), two-way ANOVA ( j , p ), one-way ANOVA with Tukey’s multiple comparisons test ( l , n , o ). 5ME-THF, 5-methyltetrahydrofolate; NAC, N -acetyl- l -cysteine; NEAA, non-essential amino acids; NS, not significant. Scale bars, 1 mm.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_8440/pmc13128440/pmc13128440__41586_2026_10216_Fig4_HTML.jpg)
